Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate the effect of aflibercept 2.0 mg in cases resistant to ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment. PURPOSE: To evaluate the anatomic and visual effect of intravitreal aflibercept 2.0 mg in cases of exudative age-related macular degeneration (AMD) with persistent fluid on optical coherence tomography (OCT) despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment at 1 and 6 months. METHODS: Retrospective review at Ophthalmic Consultants of Boston, Boston, Massachusetts, USA of exudative AMD cases with persistent fluid on regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment switched to intravitreal aflibercept 2.0 mg treatment and followed for 6 months. Tabulated data included details of prior treatments, best available visual acuity, central subfoveal thickness on registered spectral domain OCT before and after aflibercept injection centred on the anatomic fovea and macular description before and after aflibercept injection. RESULTS: A total of 353 eyes with exudative AMD were switched to aflibercept during the study period. Of these, 28 eyes in 28 patients had persistent fluid after an average of 20 regular ranibizumab/bevacizumab injections (range 7-37). At 1 month, 89% (25 eyes) showed anatomic improvement and 18% (five eyes) were dry after a single aflibercept injection. Central subfoveal thickness improved from 295 to 272 microns (p<0.001) after one aflibercept injection. After an average of 4.4 aflibercept injections (range 3-6) over 6 months, the central subfoveal thickness remained improved (274 microns, p=0.008); 64% (18 eyes) showed anatomic improvement and a quarter of eyes (25%, seven eyes) were dry. Visual acuity did not improve at 1 month (logarithm of minimum angle of resolution (logMAR) 0.54, Snellen 20/69, p=0.64) or 6 months (logMAR 0.57, Snellen 20/76, p=0.49). Treatment was well tolerated with no adverse events reported. CONCLUSIONS: A significant proportion of exudative AMD cases with persistent fluid on OCT despite regular ranibizumab 0.5 mg and/or bevacizumab 1.25 mg treatment respond anatomically to aflibercept 2.0 mg. Visual acuity did not improve. Aflibercept may be beneficial anatomically in cases of exudative AMD treated with persistent fluid on ranibizumab and/or bevacizumab.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there is emerging evidence that switching from one anti-VEGF therapy to another may result in increased response.[61][62][63][64][65]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [62]
Citations
Cites
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Self-citationRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Self-citationGoodman and Gilman's the Pharmacological Basis of Therapeutics
Thompson Coon, J. (2002) · Focus on Alternative and Complementary Therapies · doi:10.1111/j.2042-7166.2002.tb05480.x · Cited by 1,744
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Self-citationProper Method for Calculating Average Visual Acuity
Holladay, J. T. (1997) · Journal of Refractive Surgery · doi:10.3928/1081-597x-19970701-16 · Cited by 1,090
Lalwani, G. A., Rosenfeld, P. J., Fung, A. E., Dubovy, S. R., Michels, S., Feuer, W., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.01.024 · Cited by 880
Cited by
Schmidt-Erfurth, U., Chong, V., Loewenstein, A., Larsen, M., Souied, E., Schlingemann, R., Eldem, B., Monés, J., Richard, G., & Bandello, F. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305702 · Cited by 639
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Sun, X., Yang, S., & Zhao, J. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s97653 · Cited by 347
“34 119 The proposed mechanism of switching between two anti-VEGF drugs, bevacizumab and ranibizumab, could be due to the different molecular sizes and associated transport of these molecules through the retina and into the subretinal space.”
Age-Related Macular Degeneration: Advances in Management and Diagnosis
Yonekawa, Y., Miller, J. W., & Kim, I. K. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4020343 · Cited by 169
Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
Wallsh, J. O., & Gallemore, R. P. (2021) · Cells · doi:10.3390/cells10051049 · Cited by 166
Metadata
- Authors
- Cho, H., Shah, C. P., Weber, M., & Heier, J. S.
- Affiliations
- Ophthalmic Consultants of Boston (US)
- Corresponding author
- Heier, Jeffrey S
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2013-06-13
- Volume
- 97
- Issue
- 8
- Pages
- 1032-1035
- ISSN
- 0007-1161 (ISSN-L)
- 1468-2079
- OpenAlex
- W2084462826
- Cited by
- 161
- References
- 24
- Citations by year
- 2025: 4 · 2024: 4 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 1 · 2019: 9 · 2018: 14 · 2017: 21 · 2016: 31 · 2015: 32 · 2014: 31 · 2013: 4
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- British Journal of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- aflibercept, neovascular age-related macular degeneration, ranibizumab, bevacizumab, treatment-resistant macular edema, intravitreal injection, visual acuity, anti-VEGF therapy, treatment switching, optical coherence tomography, fovea, retinal pigment epithelium
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Aged, 80 and over, Drug Resistance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recombinant Fusion Proteins, Retrospective Studies, Visual Acuity, Treatment Outcome, Retreatment, Receptors, Vascular Endothelial Growth Factor, Tomography, Optical Coherence, Wet Macular Degeneration, Drug Substitution, Intravitreal Injections, Subretinal Fluid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. https://app.cochat.ai/papers/10.1136/bjophthalmol-2013-303344
- The paper
- Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013). Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. British Journal of Ophthalmology. https://doi.org/10.1136/bjophthalmol-2013-303344
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.